Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

Hepatology. 1994 Nov;20(5):1121-30.

Abstract

The quasispecies nature of hepatitis C virus genome distribution is most evident in hypervariable regions of the putative envelope 2 domain. Eight patients with chronic hepatitis C treated with interferon-alpha were studied as to heterogeneity of the hypervariable regions to clarify the implications of quasispecies. More than 10 recombinant clones generated from polymerase chain reaction-amplified products of the hypervariable regions were sequenced. The sets of clones derived from long-term responders before interferon therapy showed a significantly lower (p < 0.05) degree of sequence complexity of the hypervariable region 1 quasispecies than those from short-term ones or non-responders. The values of nucleotide diversity (the average number of nucleotide differences per site between two randomly chosen sequences) in hypervariable region 1 before interferon therapy were also significantly lower (p < 0.05) for long-term responders (mean, 2.31 x 10(-2)). In some cases, nucleotide diversity decreased remarkably during interferon therapy, whereas the values remained unchanged in other cases. In one interesting case, a short-term response was first noted with the nucleotide diversity decreasing from 13.98 x 10(-2) to 0.21 x 10(-2); namely, the diversity of the quasispecies was significantly reduced, and then a long-term response was observed after an additional course of interferon therapy. Thus, the degree of quasispecies' complexity and diversity of hypervariable region 1 was closely correlated with the responsiveness to interferon therapy in chronic hepatitis C patients, and thus may have some influence on interferon efficacy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Amino Acid Sequence
  • Base Sequence
  • Chronic Disease
  • Genome, Viral*
  • Hepacivirus / classification
  • Hepacivirus / genetics*
  • Hepatitis C / blood
  • Hepatitis C / therapy*
  • Humans
  • Interferons / therapeutic use*
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Oligonucleotide Probes / genetics

Substances

  • Oligonucleotide Probes
  • Interferons
  • Alanine Transaminase